17 results on '"Yu, Liping"'
Search Results
2. The Area Under the Curve for Insulin Autoantibodies Identifies a Group at High Risk for Diabetes in the Diabetes Autoimmunity Study in the Young (DAISY).
- Author
-
Barker, Jennifer M., Yu, Liping, Miao, Dongmei, Barriga, Katherine, Hoffman, Michelle R., Eisenbarth, George S., and Rewers, Marian
- Subjects
- *
INSULIN antibodies , *DIABETES in children , *DIABETES prevention , *AUTOANTIBODIES , *IMMUNOGLOBULINS - Abstract
Long-term studies of children at high genetic risk for type 1 diabetes (T1D) have identified groups of children with diabetes related autoantibodies. The ability to differentiate subjects at the highest risk for progression to T1D will be important for planned prevention studies. DAISY follows two high risk cohorts (young first degree relatives of subjects with T1D and neonates from the general population with moderate or high risk HLA genotypes). Subjects are screened at 9, 15 and 24 months of age and then annually for autoantibodies to insulin (IAA), GAD65 and ICA-512. Subjects who are identified as positive for any autoantibody are then tested every 3-6 months. Positive subjects were classified as follows: transiently positive (+for ≥ 1 antibody (confirmed by blinded duplicate sample testing) but negative at the most recent visit, n=82), persistently positive with no T1D (+ for ≥ 1 antibody and + at the most recent visit, n=65) and progressed to diabetes (regardless of autoantibody status, n=30). We hypothesized that characteristics of autoantibody positivity would differentiate the persistently positive children from those progressing to diabetes. The persistent and diabetes groups had a higher proportion with multiple antibodies positive at the 1st + test compared to the transient group (transient 1.2%, persistent 22%, diabetes 33% multiple antibodies at first positive, p<0.0001). Children who developed diabetes, compared with the persistent group, had more often multiple antibodies (70% vs. 35%, p<0.0001) and IAA (66% vs. 35%, p=0.003) at their last visit. To analyze the effect of IAA positivity over time, the area under the curve of IAA levels was calculated and divided by duration of the follow-up (AUC/duration). Subjects who developed diabetes had greater IAAAUC/duration of follow-up compared with persistent or transient subjects (ANOVA: p<0.0001). Cox proportional hazard modeling was used to determine the effect of IAA AUC/duration in the persistant and diabetes groups, controlling for family history and the number of positive antibodies at the last non-diabetic visit. Predictors of progression to diabetes included: HLA DR, DQ (Hazard Ratio (HR) 1.75, p = 0.02), age first positive (HR=0.609, p<0.0001) and IAAAUC/duration (HR=3.57 p=0.02). Therefore, IAA AUC may be useful for identifying subjects at high risk for progression to T1D and suggests that IAA levels are related to progression. [ABSTRACT FROM AUTHOR]
- Published
- 2007
3. Autoantibody "Subspecificity" in Type 1 Diabetes.
- Author
-
Barker, Jennifer M., Yu, Jeesvk, Yu, Liping, Wang, Jian, Miao, Dongmei, Bao, Fei, Hoffenberg, Edward, Nelson, Jerald C., Gottlieb, Peter A., Rewers, Marian, and Eisenbarth, George S.
- Subjects
- *
AUTOIMMUNE diseases , *THYROID diseases , *THYROGLOBULIN , *IMMUNOGLOBULINS , *AUTOANTIBODIES - Abstract
OBJECTIVE -- Autoimmune thyroid disease (ALT), celiac disease, and Addison's disease are characterized by the presence of autoantibodies: thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TGAb) in AIT, tissue transglutaminase antibody (TTGAb) in celiac disease, and 21-hydroxylase antibody (21-OHAb) in Addison's disease. The objective of this study was to define the prevalence of these autoantibodies and clinical disease in a population with type 1 diabetes. RESEARCH DESIGN AND METHODS -- We screened 814 individuals with type 1 diabetes for TPOAb, TGAb, TTGAb, and 21-OHAb. Clinical disease was defined by chart review. Factors related to the presence of autoimmunity and clinical disease including age at onset of type 1 diabetes, duration of diabetes, age at screening, sex, and the presence of autoantibodies were reviewed. RESULTS -- The most common autoantibodies expressed were TPOAb and/or TGAb (29%), followed by TTGAb (10.1%) and 21-OHAb (1.6%). Specific HLA DR/DQ genotypes were associated with the highest risk for expression of 21-OHAb (DRB1(*)0404-DQ8, DR3-DQ2) and TTGAb (DR3-DQ2- DR3-DQ2). The expression of thyroid autoantibodies was related to 21-OHAb but not to TTGAb. The presence of autoantibodies was associated with and predictive of disease. CONCLUSIONS -- In this large cohort of individuals with type 1 diabetes, the expression of organ-specific autoantibodies was very high. The grouping of autoantibody expression suggests common factors contributing to the clustering. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
4. Prevalence of SARS-CoV-2 Antibodies in Children and Adults with Type 1 Diabetes.
- Author
-
Jia, Xiaofan, Gesualdo, Patricia, Geno Rasmussen, Cristy, Alkanani, Aimon A., He, Ling, Dong, Fran, Rewers, Marian J., Michels, Aaron W., and Yu, Liping
- Subjects
- *
TYPE 1 diabetes , *SARS-CoV-2 , *COVID-19 , *IMMUNOGLOBULINS , *ADULTS - Abstract
Objective: As diabetes is a risk factor for severe symptoms, hospitalization, and death with COVID-19 disease, we aimed to assess the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in children and adults with and without type 1 diabetes in Colorado during 2020. Research Design and Methods: We developed a highly sensitive and specific test for antibodies against SARS-CoV-2 and measured the antibodies in children and adults with new-onset (n = 129) and established type 1 diabetes (n = 94) seen for routine diabetes care at our center between January and October 2020. The antibodies were also measured in 562 children and 102 adults from the general population of Colorado. Results: The prevalence of SARS-CoV-2 antibodies in persons with new-onset type 1 diabetes (0.8%; 95% confidence interval 0.1%-4.2%) or those with established disease (4.3%; 1.7%-10.4%) did not differ from that in the general population children (2.8%; 1.8%-4.6%) or adults (3.9%; 1.5%-9.7%). In a subset of individuals with positive antibodies (n = 31), antibodies remained positive for up to 9 months, although the levels decreased starting 3 months after the infection (P = 0.007). Conclusions: From January to October 2020, the prevalence of SARS-CoV-2 antibodies were not different in children and adults with and without type 1 diabetes in Colorado. We found no evidence for increased prevalence of COVID-19 infections among youth with newly diagnosed type 1 diabetes. (COMIRB Protocol 20-1007). [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Hierarchical Order of Distinct Autoantibody Spreading and Progression to Type 1 Diabetes in the TEDDY Study.
- Author
-
Vehik, Kendra, Bonifacio, Ezio, Lernmark, Åke, Yu, Liping, Williams, Alistair, Schatz, Desmond, Rewers, Marian, She, Jin-Xiong, Toppari, Jorma, Hagopian, William, Akolkar, Beena, Ziegler, Anette G., Krischer, Jeffrey P., Barbour, Aaron, Bautista, Kimberly, Baxter, Judith, Felipe-Morales, Daniel, Driscoll, Kimberly, Frohnert, Brigitte I., and Stahl, Marisa
- Subjects
- *
TYPE 1 diabetes , *HIV seroconversion , *ZINC supplements , *SEROCONVERSION , *ZINC transporters , *AUTOANTIBODIES , *DISEASE progression , *RESEARCH , *HLA-B27 antigen , *IMMUNOGLOBULINS , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *DISEASE susceptibility , *ENZYMES , *RESEARCH funding , *LONGITUDINAL method - Abstract
Objective: The first-appearing β-cell autoantibody has been shown to influence risk of type 1 diabetes (T1D). Here, we assessed the risk of autoantibody spreading to the second-appearing autoantibody and further progression to clinical disease in The Environmental Determinants of Diabetes in the Young (TEDDY) study.Research Design and Methods: Eligible children with increased HLA-DR-DQ genetic risk for T1D were followed quarterly from age 3 months up to 15 years for development of a single first-appearing autoantibody (GAD antibody [GADA], insulin autoantibody [IAA], or insulinoma antigen-2 autoantibody [IA-2A]) and subsequent development of a single second-appearing autoantibody and progression to T1D. Autoantibody positivity was defined as positivity for a specific autoantibody at two consecutive visits confirmed in two laboratories. Zinc transporter 8 autoantibody (ZnT8A) was measured in children who developed another autoantibody.Results: There were 608 children who developed a single first-appearing autoantibody (IAA, n = 282, or GADA, n = 326) with a median follow-up of 12.5 years from birth. The risk of a second-appearing autoantibody was independent of GADA versus IAA as a first-appearing autoantibody (adjusted hazard ratio [HR] 1.12; 95% CI 0.88-1.42; P = 0.36). Second-appearing GADA, IAA, IA-2A, or ZnT8A conferred an increased risk of T1D compared with children who remained positive for a single autoantibody, e.g., IAA or GADA second (adjusted HR 6.44; 95% CI 3.78-10.98), IA-2A second (adjusted HR 16.33; 95% CI 9.10-29.29; P < 0.0001), or ZnT8A second (adjusted HR 5.35; 95% CI 2.61-10.95; P < 0.0001). In children who developed a distinct second autoantibody, IA-2A (adjusted HR 3.08; 95% CI 2.04-4.65; P < 0.0001) conferred a greater risk of progression to T1D as compared with GADA or IAA. Additionally, both a younger initial age at seroconversion and shorter time to the development of the second-appearing autoantibody increased the risk for T1D.Conclusions: The hierarchical order of distinct autoantibody spreading was independent of the first-appearing autoantibody type and was age-dependent and augmented the risk of progression to T1D. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
6. Time-Resolved Autoantibody Profiling Facilitates Stratification of Preclinical Type 1 Diabetes in Children.
- Author
-
Endesfelder, David, Wolfgang zu Castell, Bonifacio, Ezio, Rewers, Marian, Hagopian, William A., Jin‐Xiong She, Lernmark, Åke, Toppari, Jorma, Vehik, Kendra, Williams, Alistair J. K., Liping Yu, Akolkar, Beena, Krischer, Jeffrey P., Ziegler, Anette-G., Achenbach, Peter, Castell, Wolfgang Zu, She, Jin-Xiong, Yu, Liping, TEDDY Study Group, and Zu Castell, Wolfgang
- Subjects
- *
AUTOANTIBODIES , *DIABETES in children , *TYPE 1 diabetes , *AUTOANTIBODY analysis , *DISEASE progression , *INSULINOMA , *ALGORITHMS , *COMPARATIVE studies , *IMMUNOGLOBULINS , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *EVALUATION research , *KAPLAN-Meier estimator - Abstract
Progression to clinical type 1 diabetes varies among children who develop β-cell autoantibodies. Differences in autoantibody patterns could relate to disease progression and etiology. Here we modeled complex longitudinal autoantibody profiles by using a novel wavelet-based algorithm. We identified clusters of similar profiles associated with various types of progression among 600 children from The Environmental Determinants of Diabetes in the Young (TEDDY) birth cohort study; these children developed persistent insulin autoantibodies (IAA), GAD autoantibodies (GADA), insulinoma-associated antigen 2 autoantibodies (IA-2A), or a combination of these, and they were followed up prospectively at 3- to 6-month intervals (median follow-up 6.5 years). Children who developed multiple autoantibody types (n = 370) were clustered, and progression from seroconversion to clinical diabetes within 5 years ranged between clusters from 6% (95% CI 0, 17.4) to 84% (59.2, 93.6). Children who seroconverted early in life (median age <2 years) and developed IAA and IA-2A that were stable-positive on follow-up had the highest risk of diabetes, and this risk was unaffected by GADA status. Clusters of children who lacked stable-positive GADA responses contained more boys and lower frequencies of the HLA-DR3 allele. Our novel algorithm allows refined grouping of β-cell autoantibody-positive children who distinctly progressed to clinical type 1 diabetes, and it provides new opportunities in searching for etiological factors and elucidating complex disease mechanisms. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
7. The Use of Electrochemiluminescence Assays to Predict Autoantibody and Glycemic Progression Toward Type 1 Diabetes in Individuals with Single Autoantibodies.
- Author
-
Sosenko, Jay M., Liping Yu, Skyler, Jay S., Krischer, Jeffrey P., Gottlieb, Peter A., Boulware, David, Miao, Dongmei, Palmer, Jerry P., Steck, Andrea K., and Yu, Liping
- Subjects
- *
ELECTROCHEMILUMINESCENCE , *TYPE 1 diabetes , *GLYCEMIC control , *PATIENTS , *BLOOD sugar analysis , *AUTOANTIBODIES , *ENZYMES , *IMMUNOGLOBULINS , *LUMINESCENCE spectroscopy , *DISEASE progression - Abstract
Background: Electrochemiluminescence (ECL) assays have shown promise for enhancing the prediction of type 1 diabetes (T1D) with autoantibodies. We thus studied relatives of T1D patients to determine whether ECL assays can be used to refine risk assessments for T1D among individuals either positive for single GADA or single mIAA autoantibodies.Subjects and Methods: TrialNet Pathway to Prevention (PTP) study participants with either GADA or mIAA single autoantibodies were tested for ECL positivity during their participation in the TrialNet PTP study. Those ECL positive (ECL+) were compared with those ECL negative (ECL-) for conversion to multiple autoantibodies, 6-month glycemic progression (PS6M), and the progression to T1D.Results: The progression to multiple autoantibodies was significantly higher for those GADA/ECL+ (n = 107) than those GADA/ECL- (n = 78) (P = 0.001) and for those mIAA/ECL+ (n = 24) than those mIAA/ECL- (n = 63) (P < 0.001). The hazard ratios with 95% confidence intervals were 3.42 (1.58-7.39; P < 0.01) for GADA and 8.15 (3.02-22.00; P < 0.001) for mIAA. GADA/ECL+ and mIAA/ECL+ participants had significantly higher PS6M values than their ECL- counterparts (P = 0.001 for GADA and P = 0.009 for mIAA). Of those GADA/ECL+, 14% progressed to T1D; of those mIAA/ECL+, 17% progressed to T1D. Only 1 individual (positive for GADA) of the 141 who was ECL- progressed to T1D (median follow-up: 5 years).Conclusion: ECL measurements appear to have utility for natural history studies and prevention trials of individuals with single autoantibodies. Those ECL+ are at appreciable risk for developing multiple autoantibodies and for glycemic progression toward T1D, whereas those ECL- are at very low risk. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
8. Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?
- Author
-
Fouts, Alexandra, Pyle, Laura, Liping Yu, Dongmei Miao, Michels, Aaron, Krischer, Jeffrey, Sosenko, Jay, Gottlieb, Peter, Steck, Andrea K., Yu, Liping, Miao, Dongmei, and Type 1 Diabetes TrialNet Study Group
- Subjects
- *
ELECTROCHEMILUMINESCENCE , *TYPE 1 diabetes , *AUTOANTIBODIES , *GLUCOSE tolerance tests , *C-peptide , *BLOOD sugar , *GLYCOSYLATED hemoglobin , *IMMUNOGLOBULINS , *LIGHT , *LONGITUDINAL method , *RESEARCH funding , *TIME , *PROPORTIONAL hazards models , *DISEASE progression , *DIAGNOSIS - Abstract
Objective: To explore whether electrochemiluminescence (ECL) assays can help improve prediction of time to type 1 diabetes in the TrialNet autoantibody-positive population.Research Design and Methods: TrialNet subjects who were positive for one or more autoantibodies (microinsulin autoantibody, GAD65 autoantibody [GADA], IA-2A, and ZnT8A) with available ECL-insulin autoantibody (IAA) and ECL-GADA data at their initial visit were analyzed; after a median follow-up of 24 months, 177 of these 1,287 subjects developed diabetes.Results: Univariate analyses showed that autoantibodies by radioimmunoassays (RIAs), ECL-IAA, ECL-GADA, age, sex, number of positive autoantibodies, presence of HLA DR3/4-DQ8 genotype, HbA1c, and oral glucose tolerance test (OGTT) measurements were all significantly associated with progression to diabetes. Subjects who were ECL positive had a risk of progression to diabetes within 6 years of 58% compared with 5% for the ECL-negative subjects (P < 0.0001). Multivariate Cox proportional hazards models were compared, with the base model including age, sex, OGTT measurements, and number of positive autoantibodies by RIAs. The model with positivity for ECL-GADA and/or ECL-IAA was the best, and factors that remained significantly associated with time to diabetes were area under the curve (AUC) C-peptide, fasting C-peptide, AUC glucose, number of positive autoantibodies by RIAs, and ECL positivity. Adding ECL to the Diabetes Prevention Trial risk score (DPTRS) improved the receiver operating characteristic curves with AUC of 0.83 (P < 0.0001).Conclusions: ECL assays improved the ability to predict time to diabetes in these autoantibody-positive relatives at risk for developing diabetes. These findings might be helpful in the design and eligibility criteria for prevention trials in the future. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
9. Feasibility of screening for T1D and celiac disease in a pediatric clinic setting.
- Author
-
Gesualdo, Patricia D, Bautista, Kimberly A, Waugh, Kathleen C, Yu, Liping, Norris, Jill M, Rewers, Marian J, and Baxter, Judith
- Subjects
- *
CELIAC disease diagnosis , *AUTOIMMUNE diseases , *BLOOD testing , *COMMUNITY health services , *DIABETIC acidosis , *IMMUNOGLOBULINS , *TYPE 1 diabetes , *MEDICAL screening , *PARENTS , *PATIENT satisfaction , *PEDIATRICS , *RESEARCH funding , *ACCESS to information , *PATIENT selection , *GLYCEMIC control , *DIAGNOSIS - Abstract
Objective Type 1 diabetes ( T1D) or celiac disease ( CD) develops in at least 2% of the general population. Early detection of disease-specific autoimmunity and subsequent monitoring would be possible if screening tests were more widely available. Currently, screening for islet autoimmunity is available only in a research setting, and CD-specific autoimmunity screening is limited to those in high-risk groups. This study assessed the feasibility of incorporating T1D and CD autoantibody screening into a pediatric practice. Methods Patient engagement strategies, blood collection preference, blood sample volume, rate of autoantibody detection in the general population, and parental satisfaction were assessed. Over 5 weeks, research staff recruited 200 patients, aged 2-6 yr from two pediatric practices in the Denver area to be screened for islet autoantibodies (IAs) and the transglutaminase antibody. Results Of the 765 parents approached, 200 (26%) completed the same-day screening. Of the 565 subjects who did not complete the screening, 345 expressed interest, but were unable to make a participation decision. A finger stick, compared with a venous draw, was the preferred method of sample collection. Both methods yielded sufficient blood volume for autoantibody determination. IAs or the transglutaminase antibody were detected in 11 subjects. Parents expressed satisfaction with all aspects of participation. Conclusions The results of this study suggest that it is feasible to conduct this type of screening in a pediatric clinic. Such screening could lead to increased disease awareness and the possible benefits that can result from early detection. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
10. Predictors of slow progression to diabetes in children with multiple islet autoantibodies.
- Author
-
Steck, Andrea K., Dong, Fran, Waugh, Kathleen, Frohnert, Brigitte I., Yu, Liping, Norris, Jill M., and Rewers, Marian J.
- Subjects
- *
DIABETES in children , *JUVENILE diseases , *AUTOANTIBODIES , *IMMUNOGLOBULINS , *AUTOIMMUNITY - Abstract
Although most children with multiple islet autoantibodies develop type 1 diabetes, rate of progression is highly variable. The goal of this study was to explore potential factors involved in rate of progression to diabetes in children with multiple islet autoantibodies. The Diabetes Autoimmunity Study in the Young (DAISY) has followed 118 children with multiple islet autoantibodies for progression to diabetes. After excluding 27 children currently diabetes-free but followed for <10 years, the study population was grouped into: rapid progressors (N = 39) who developed diabetes in <5 years; moderate progressors (N = 25), diagnosed with diabetes within 5–10 years; and slow progressors (N = 27), diabetes-free for >10 years. Islet autoimmunity appeared at 4.0 ± 3.5, 3.2 ± 1.8 and 5.8 ± 3.1 years of age in rapid, moderate and slow progressors, respectively (p = 0.006). Insulin autoantibody levels were lower in slow progressors compared to moderate and rapid progressors. The groups did not differ by gender, ethnicity, family history, susceptibility HLA and non-HLA genes. The rate of development of individual islet autoantibodies including mIAA, GADA, IA-2A and ZnT8A were all slower in the slow versus moderate/rapid progressors. In multivariate analyses, older age at seroconversion and lower initial mIAA levels independently predicted slower progression to diabetes. Later onset of islet autoimmunity and lower autoantibody levels predicted slower progression to diabetes among children with multiple islet autoantibodies. These factors may need to be considered in the design of trials to prevent type 1 diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
11. Electrochemiluminescence assays for insulin and glutamic acid decarboxylase autoantibodies improve prediction of type 1 diabetes risk.
- Author
-
Miao, Dongmei, Steck, Andrea K., Zhang, Li, Guyer, K. Michelle, Jiang, Ling, Armstrong, Taylor, Muller, Sarah M., Krischer, Jeffrey, Rewers, Marian, Yu, Liping, and Type 1 Diabetes TrialNet Study Group
- Subjects
- *
TYPE 1 diabetes , *ELECTROCHEMILUMINESCENCE , *DISEASE progression , *FOLLOW-up studies (Medicine) , *MEDICAL statistics , *DIAGNOSIS , *DIABETES risk factors , *ENZYME metabolism , *AUTOANTIBODIES , *COMPARATIVE studies , *ENZYMES , *IMMUNOGLOBULINS , *LIGHT , *RESEARCH methodology , *MEDICAL cooperation , *MEDICAL screening , *PREDIABETIC state , *RESEARCH , *RESEARCH funding , *EVALUATION research , *PREDICTIVE tests , *GENOTYPES - Abstract
We recently developed new electrochemiluminescence (ECL) insulin autoantibody (IAA) and glutamic acid decarboxylase 65 autoantibody (GADA) assays that discriminate high-affinity, high-risk diabetes-specific autoantibodies from low-affinity, low-risk islet autoantibodies (iAbs) detected by radioassay (RAD). Here, we report a further validation of the ECL-IAA and -GADA assays in 3,484 TrialNet study participants. The ECL assay and RAD were congruent in those with prediabetes and in subjects with multiple autoantibodies, but only 24% (P<0.0001) of single RAD-IAA-positive and 46% (P<0.0001) of single RAD-GADA-positive were confirmed by the ECL-IAA and -GADA assays, respectively. During a follow-up (mean, 2.4 years), 51% of RAD-IAA-positive and 63% of RAD-GADA-positive subjects not confirmed by ECL became iAb negative, compared with only 17% of RAD-IAA-positive (P<0.0001) and 15% of RAD-GADA-positive (P<0.0001) subjects confirmed by ECL assays. Among subjects with multiple iAbs, diabetes-free survival was significantly shorter if IAA or GADA was positive by ECL and negative by RAD than if IAA or GADA was negative by ECL and positive by RAD (P<0.019 and P<0.0001, respectively). Both positive and negative predictive values in terms of progression to type 1 diabetes mellitus were superior for ECL-IAA and ECL-GADA, compared with RADs. The prevalence of the high-risk human leukocyte antigen-DR3/4, DQB1*0302 genotype was significantly higher in subjects with RAD-IAA or RAD-GADA confirmed by ECL. In conclusion, both ECL-IAA and -GADA are more disease-specific and better able to predict the risk of progression to type 1 diabetes mellitus than the current standard RADs. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
12. Inhibition of Increased Circulating Tfh Cell by Anti-CD20 Monoclonal Antibody in Patients with Type 1 Diabetes.
- Author
-
Xu, Xinyu, Shi, Yun, Cai, Yun, Zhang, Qingqing, Yang, Fan, Chen, Heng, Gu, Yong, Zhang, Mei, Yu, Liping., and Yang, Tao
- Subjects
- *
TYPE 1 diabetes , *TREATMENT of diabetes , *T helper cells , *IMMUNOGLOBULINS , *AUTOIMMUNE diseases , *RITUXIMAB , *FOLLOW-up studies (Medicine) , *B cells , *MESSENGER RNA - Abstract
Objectives: Follicular helper T (Tfh) cells exert an important role in autoimmune diseases. Whether it might be involved in type 1 diabetes (T1D) is unknown. Our aim was to investigate the role of Tfh cells in patients with T1D and the effect of anti-CD20 monoclonal antibody (rituximab) on Tfh cells from T1D patients. Patients and Methods: Fifty-four patients with T1D and 37 healthy controls were enrolled in the current study. 20 of those patients were treated with rituximab. The frequencies of circulating CD4+CXCR5+ICOS+T cells were analyzed by flow cytometry. The serum autoantibodies were detected by radioligand assay. The levels of IL-21, IL-6 and BCL-6 were assessed using ELISA and/or real-time PCR. Results: Increased frequencies of circulating Tfh cells together with enhanced expression of IL-21 were detected in patients. The correlation between the frequencies of circulating Tfh cells and the serum autoantibodies or C-peptide level was comfirmed. After rituximab therapy, follow-up analysis demonstrated that the frequencies of circulating Tfh cell and serum IA2A were decreased. The levels of IL-21, IL-6 and Bcl-6 mRNA were decreased after treatment. Furthermore, beta cell function in 10 of 20 patients was improved. Conclusions: These data indicate Tfh cells may participate in the T1D-relatede immune responses and B cells might play a role in the development of Tfh responses in the disease progression. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
13. Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1.
- Author
-
Orban, Tihamer, Sosenko, Jay M., Cuthbertson, David, Krischer, Jeffrey P., Skyler, Jay S., Jackson, Richard, Yu, Liping, Palmer, Jerry P., Schatz, Desmond, and Eisenbarth, George
- Subjects
- *
DIABETES , *AUTOANTIBODIES , *ISLANDS of Langerhans , *PANCREAS , *IMMUNOGLOBULINS - Abstract
OBJECTIVE -- There is limited information from large-scale prospective studies regarding the prediction of type 1 diabetes by specific types of pancreatic islet autoantibodies, either alone or in combination. Thus, we studied the extent to which specific autoantibodies are predictive of type 1 diabetes. RESEARCH DESIGN AND METHODS -- Two cohorts were derived from the first screening for islet cell autoantibodies (ICAs) in the Diabetes Prevention Trial-Type 1 (DPT-1). Autoantibodies to GAD 65 (GAD65), insulinoma-associated antigen-2 (ICA512), and insulin (micro-IAA [mIAA]) were also measured. Participants were followed for the occurrence of type 1 diabetes. One cohort (Questionnaire) included those who did not enter the DPT-1 trials, but responded to questionnaires (n = 28,507, 2.4% ICA[sup +]). The other cohort (Trials) included DPT-1 participants (n = 528, 83.3% ICA[sup +]). RESULTS -- In both cohorts autoantibody number was highly predictive of type 1 diabetes (P < 0.001). The Questionnaire cohort was used to assess prediction according to the type of autoantibody. As single autoantibodies, 1CA (3.9%), GAD65 (4.4%), and ICA512 (4.6%) were similarly predictive of type 1 diabetes in proportional hazards models (P < 0.001 for all). However, no subjects with m1AA as single autoantibodies developed type 1 diabetes. As second autoantibodies, all except mIAA added significantly (P < 0.001) to the prediction of type 1 diabetes. Within the positive range, GAD65 and ICA autoantibody titers were predictive of type 1 diabetes. CONCLUSIONS -- The data indicate that the number of autoantibodies is predictive of type 1 diabetes. However, mIAA is less predictive of type 1 diabetes than other autoantibodies. Autoantibody number, type of autoantibody, and autoantibody titer must be carefully considered in planning prevention trials for type 1 diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
14. Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23.
- Author
-
Liu, Edwin, Moriyama, Hiroaki, Abiru, Norio, Miao, Dongmei, Yu, Liping, Taylor, Robert M., Frankelman, Fred D., Eisenbarth, George S., and Finkelman, Fred D
- Subjects
- *
INSULIN , *PEPTIDES , *AUTOANTIBODIES , *ANAPHYLAXIS , *ANIMAL experimentation , *COMPARATIVE studies , *ENKEPHALINS , *IMMUNIZATION , *IMMUNOGLOBULINS , *RESEARCH methodology , *MEDICAL cooperation , *MICE , *PROTEIN precursors , *PYRIDINE , *RESEARCH , *EVALUATION research - Abstract
There is evidence that amino acids 9-23 of the insulin B chain are a major target of anti-islet autoimmunity in type 1 diabetes. Administration of this peptide to NOD mice prevents diabetes, and phase I trials of an altered peptide ligand of B:9-23 are underway in humans. We were interested in long-term subcutaneous therapeutic administration of B:9-23 without adjuvant. To our initial surprise, the peptide consistently induced fatal anaphylaxis in NOD mice after 6 weeks of administration. Anaphylaxis could be blocked by a combination of antihistamine and platelet-activating factor antagonist (but neither alone) or by a combination of anti-IgG receptor and anti-IgE antibodies. High titers of anti-B:9-23 antibodies were induced within 3-4 weeks of immunization with the peptide. Peptide B:13-23 also induced anaphylaxis and was more potent than peptide B:9-23. Antibodies induced by peptide B:9-23 and peptide B:13-23 did not cross-react with each other. Thus, the insulin peptides B:9-23 and B:13-23, even when administered subcutaneously in the absence of adjuvant, can induce a dramatic humoral response leading to fatal anaphylaxis in NOD mice. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
15. A Longitudinal Study of GAD65 and ICA512 Autoantibodies During the Progression to Type 1 Diabetes in Diabetes Prevention Trial--Type 1 (DPT-1) Participants.
- Author
-
SOSENKO, JAY M., SKYLER, JAY S., PALMER, JERRY P., KRISCHER, JEFFREY P., CUTHBERTSON, DAVID, YU, LIPING, SCHATZ, DESMOND A., ORBAN, TIHAMER, and EISENBARTH, GEORGE
- Subjects
- *
DIABETES , *AUTOANTIBODIES , *LONGITUDINAL method , *IMMUNOGLOBULINS , *AUTOIMMUNITY - Abstract
OBJECTIVE--We examined changes in GAD65 and ICA-512 autoantibodies (GADA and IA-2A) during progression to type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS--Diabetes Prevention Trial--Type 1 (DPT-1) participants were assessed for changes in positivity and titers of GADA and IA-2A during the progression to T1D. RESULTS--Among 99 progressors to T1D with GADA and IA-2A measurements at baseline and diagnosis (mean interval = 3.3 6 1.5 years), GADA positivity changed little and GADA titers decreased (P < 0.01). In contrast, both IA-2A positivity and titers increased substantially (P < 0.001). Even among those positive at baseline, IA-2A titers increased from baseline to diagnosis (n =5 7; P < 0.001), whereas GADA titers decreased (n=8 0; P < 0.01). The same patterns of change were also evident among those positive for both autoantibodies (n=48) at baseline. CONCLUSIONS--IA-2A titers increase during the years before the diagnosis of T1D, even among those positive for IA-2A. In contrast, GADA titers tend to decline during those years. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
16. Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: diabetes autoimmunity study in the young.
- Author
-
Steck AK, Johnson K, Barriga KJ, Miao D, Yu L, Hutton JC, Eisenbarth GS, Rewers MJ, Steck, Andrea K, Johnson, Kelly, Barriga, Katherine J, Miao, Dongmei, Yu, Liping, Hutton, John C, Eisenbarth, George S, and Rewers, Marian J
- Subjects
- *
AGE factors in disease , *AUTOANTIBODIES , *ENZYMES , *IMMUNOGLOBULINS , *INSULIN , *ISLANDS of Langerhans , *TYPE 1 diabetes , *LONGITUDINAL method , *RESEARCH funding , *DISEASE progression , *DIAGNOSIS - Abstract
Objective: We evaluated predictors of progression to diabetes in children with high-risk HLA genotypes and persistent islet autoantibodies.Research Design and Methods: The Diabetes Autoimmunity Study in the Young (DAISY) followed 2,542 children with autoantibodies measured to GAD, IA-2, and insulin.Results: Persistent islet autoantibodies developed in 169 subjects, and 55 of those progressed to diabetes. Children expressing three autoantibodies showed a linear progression to diabetes with 74% cumulative incidence by the 10-year follow-up compared with 70% with two antibodies and 15% with one antibody (P < 0.0001). Both age of appearance of first autoantibody and insulin autoantibody (IAA) levels, but not GAD or IA-2 autoantibodies, were major determinants of the age of diabetes diagnosis (r = 0.79, P < 0.0001).Conclusions: In the DAISY cohort, 89% of children who progressed to diabetes expressed two or more autoantibodies. Age of diagnosis of diabetes is strongly correlated with age of appearance of first autoantibody and IAA levels. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
17. Heterophile antibodies masquerade as interferon-alpha in subjects with new-onset type 1 diabetes.
- Author
-
Aly, Theresa, Devendra, Devasenan, Barker, Jennifer, Liu, Edwin, Yu, Liping, and Eisenbarth, George S
- Subjects
- *
ANIMAL experimentation , *COMPARATIVE studies , *ENZYME-linked immunosorbent assay , *IMMUNOGLOBULINS , *TYPE 1 diabetes , *RESEARCH methodology , *MEDICAL cooperation , *MICE , *PROTEINS , *REFERENCE values , *RESEARCH , *EVALUATION research ,RESEARCH evaluation - Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.